Annual Drug Patent Expirations for XIFAXAN
Xifaxan is a drug marketed by Salix Pharms and is included in one NDA. It is available from two suppliers. There are twenty-seven patents protecting this drug and two Paragraph IV challenges.
Drug patent litigation for XIFAXAN.
This drug has one hundred and eigthy-two patent family members in thirty-nine countries.
The generic ingredient in XIFAXAN is rifaximin. Two suppliers are listed for this compound. Additional details are available on the rifaximin profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
